SEVALENT, Bexson Biomedical’s disrupting offer ready for the small molecule injectable market, received patent allowance by the USPTO for “Complexing Agent Salt Formulations of Pharmaceutical Compounds.” 

The company’s formulation technology enables wearable, home health solutions of various types of medicines priorly delivered exclusively in an intravenous (IV) manner to now be administered subcutaneously providing the important opportunity to regulate dosage.

The new platform is …

Full story available on Benzinga.com